Month: March 2022

Company maintains strong cash position of $189.7 million SOUTH SAN FRANCISCO, Calif., March 10, 2022 (GLOBE NEWSWIRE) — RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology, today reported financial results for the fourth quarter and year ended December 31, 2021. “2021 was a significant year for RAPT, with progress in both of our lead programs,” said Brian Wong, M.D., Ph.D., President and Chief Executive Officer of RAPT Therapeutics. “We reported positive results for RPT193 from our Phase 1b clinical trial in atopic dermatitis and are excited about RPT193’s potential as a safe, once-daily oral drug for multiple inflammatory...

Company to host conference call at 4:30 PM EST today, March 10, 2022 SEATTLE and VANCOUVER, British Columbia, March 10, 2022 (GLOBE NEWSWIRE) — Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced fourth quarter and year-end 2021 financial results and provided an update on the cytisinicline clinical development program. Recent Business HighlightsInitiated ORCA-3, the second Phase 3 trial, in 750 adult smokers at 15 clinical sites in the United States Announced last subject and last follow-up visit in the Phase 3 ORCA-2 trial of cytisinicline for smoking cessation Entered into a $25 million loan facility with Silicon Valley Bank  Facilitated Key Opinion Leader virtual...

Company Achieves 12th Consecutive Year of Net Sales and Adjusted EBITDA Growth and Adjusted EBITDA Margin Expansion1 Delivers Record Fourth Quarter Year-Over-Year Net Sales Growth of 24.1% Introduces Full Fiscal Year 2022 Guidance LATHAM, N.Y., March 10, 2022 (GLOBE NEWSWIRE) — Latham Group, Inc. (“Latham” or “the Company”) (Nasdaq: SWIM), the largest designer, manufacturer, and marketer of in-ground residential swimming pools in North America, Australia, and New Zealand, today announced financial results for the fourth quarter and full fiscal year ended December 31, 2021. Fourth Quarter Fiscal 2021 Highlights:Net sales of $138.9 million, up 24.1% year-over-year Net loss of $6.0 million versus net loss of $2.7 million in the prior year period, representing a 4.3% net loss margin Adjusted EBITDA of $27.3 million,...

Testing program underway for lead product candidate, the Symphony IL-6 Test, in support of an FDA Marketing Application, planned for Q3 2022 2021 ended with approximately $19 million in cash expected to fund operations beyond the date of our anticipated regulatory approval and initial commercialization of the IL-6 Test ACTON, Mass., March 10, 2022 (GLOBE NEWSWIRE) — Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay”, “the Company”) a late-stage, pre-revenue diagnostics company focused on developing cost-effective, rapid, near-patient products for triage and monitoring of disease progression, today announced financial results for the fourth quarter and full year ended December 31, 2021 and provided a corporate update, including on the Company’s first product candidate, the IL-6 Test. “Bluejay had a very productive 2021. We substantially...

Record Full Year Net Sales Increased 22% to $380 million driven by Vita Coco Coconut Water Growth of 39% Fourth Quarter Net Sales Increased 25% to $87 Million For Fiscal Year 2022, Expect Continued Strong Net Sales Growth of 16-20% NEW YORK, March 10, 2022 (GLOBE NEWSWIRE) — The Vita Coco Company, Inc. (NASDAQ:COCO) (“Vita Coco” or “the Company”), a leading high-growth platform of better-for-you beverage brands, today announced financial results for the fourth quarter and full year ended December 31, 2021. Fourth Quarter 2021 Highlights Compared to Prior YearNet sales grew 25% to $87 million driven by Vita Coco Coconut Water growth of 61% Gross profit was $22 million, or 25% of net sales down from $23 million, or 32% of net sales Net loss attributable to shareholders was $3 million, or $0.06 per diluted share, compared to net...

All figures quoted in U.S. dollars unless otherwise noted: Performance Highlights:2021 Q4 revenue of $695 million; 1,087 equivalent units (“EUs”) delivered, with 31% coming from battery- and fuel cell-electric vehicles (“ZEBs”). Full year sales of $2.3 billion; 3,783 EUs delivered, with 18% ZEBs. 2021 Q4 Adjusted EBITDA(2) of $26 million; Net Loss per Share of $0.12 and Adjusted Net Loss per Share(2) of $0.21. Full year Adjusted EBITDA(2) of $164 million; Net Loss per Share of $0.21 and Adjusted Net Loss Per Share(2) of $0.17. Ending liquidity(2) position of $794 million. Raised C$738 million in debt and equity in 2021. Ending total backlog position (both firm and options) of 8,448 EUs (valued at $4.5 billion(2)), with active public bid universe up 70% year-over-year. ZEB backlog now 1,414 EUs, or 17%, of total...

Achieves 13% annual growth in recurring revenue and fourth quarter growth of 3% over Q3 2021 OTTAWA, March 10, 2022 (GLOBE NEWSWIRE) — ProntoForms Corporation (TSXV: PFM), the global leader in no-code app development platforms for field teams, announced today its annual and fourth quarter (Q4) financial results for the period ended December 31, 2021. All amounts are in US dollars unless otherwise stated. “We are pleased to report that our Annual Recurring Revenue Base (ARR) increased by 15.6% in 2021 compared to 8.7% in 2020. The growth in the base has improved but we are committed to getting more growth through an enterprise expansion focus. Our base is now $19.8 million with 41% from customers with greater than $100,000 of ARR,” said Alvaro Pombo, Founder and Chief Executive Officer. Mr. Pombo continued, “Our customers need to...

– Conference call to be held on March 10, 2022 at 8:30 am ET/1:30 pm GMT – LONDON, March 10, 2022 (GLOBE NEWSWIRE) — Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced its operational and financial results for the fourth quarter and full year ended December 31, 2021. “We rounded off the 2021 financial year announcing a collaboration with Blackstone Life Sciences, adding $150M in capital with an additional $100M in potential milestone payments triggered by future development progress of obe-cel, as well as positive clinical data from our pipeline, notably data from the Phase 1b portion of the FELIX study of obe-cel in adult ALL patients. Recruitment is ongoing in the Phase 2 portion of this pivotal study and we look...